"Carmustine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
| Descriptor ID |
D002330
|
| MeSH Number(s) |
D02.654.692.247 D02.948.594.247
|
| Concept/Terms |
Carmustine- Carmustine
- BCNU
- N,N'-Bis(2-Chloroethyl)-N-Nitrosourea
- 1,3-Bis(2-Chloroethyl)-1-Nitrosourea
- FIVB
|
Below are MeSH descriptors whose meaning is more general than "Carmustine".
Below are MeSH descriptors whose meaning is more specific than "Carmustine".
This graph shows the total number of publications written about "Carmustine" by people in this website by year, and whether "Carmustine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carmustine" by people in Profiles.
-
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. Apoptosis. 2016 Mar; 21(3):312-28.
-
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. Cancer Chemother Pharmacol. 2000; 45(3):239-46.
-
Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease. Anticancer Drugs. 1993 May; 4 Suppl 1:13-6.
-
High-dose chemotherapy-induced platelet defect: inhibition of platelet signal transduction pathways. Mol Pharmacol. 1993 Jan; 43(1):37-44.
-
Characterization of T lymphocyte clones isolated from BCNU-cured LSA mice. Int J Cell Cloning. 1991 Nov; 9(6):594-605.
-
Immunomodulatory effects of nitrosoureas on the phenotype and functions of T cells in the thymus and periphery. Immunopharmacology. 1990 Nov-Dec; 20(3):153-64.
-
Role of IL-2, IL-4 and IL-6 in the growth and differentiation of tumor-specific CD4+ T helper and CD8+ T cytotoxic cells. Int J Cancer. 1990 Jun 15; 45(6):1096-104.
-
Platelets acquire a secretion defect after high-dose chemotherapy. Cancer. 1990 Apr 15; 65(8):1711-6.
-
Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res. 1989 Dec 01; 49(23):6587-92.
-
Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036. Anticancer Res. 1989 Nov-Dec; 9(6):1617-22.